425 related articles for article (PubMed ID: 32749938)
1. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
3. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
4. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
6. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract][Full Text] [Related]
9. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C
Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492
[TBL] [Abstract][Full Text] [Related]
10. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
[TBL] [Abstract][Full Text] [Related]
11. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
12. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.
Watanabe G; Mise Y; Oba M; Saiura A; Inoue Y; Takahashi Y; Kishi Y; Suyama K; Takayama T; Noie T; Nishioka Y; Akamatsu N; Arita J; Kokudo N; Hasegawa K
HPB (Oxford); 2022 Aug; 24(8):1245-1251. PubMed ID: 35216869
[TBL] [Abstract][Full Text] [Related]
14. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
15. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
17. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
18. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
19. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Oki E; Emi Y; Yamanaka T; Uetake H; Muro K; Takahashi T; Nagasaka T; Hatano E; Ojima H; Manaka D; Kusumoto T; Katayose Y; Fujiwara T; Yoshida K; Unno M; Hyodo I; Tomita N; Sugihara K; Maehara Y
Br J Cancer; 2019 Jul; 121(3):222-229. PubMed ID: 31285591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]